Vectura Group

Equities

VEC

GB00BKM2MW97

Delayed London S.E. Other stock markets 11:35:22 2021-10-18 am EDT			5-day change	1st Jan Change
164.8 ^GBX	-.--%		-.--%	-.--%

Apr. 16	Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate	CI
2021	EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation	CI

Vectura : Notification of Major Interest In Shares

June 16, 2016 at 10:54 am EDT

The voting rights are managed and controlled by Aviva Investors Global Services Limitedand Friends Provident International Limited, with the following chain of controlled undertakings:-

Aviva Investors Global Services Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Investors Holdings Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Aviva Investors Global Services Limited (wholly owned subsidiary of Aviva Investors Holdings Limited)

Friends Provident International Limited:

· Aviva plc (Parent Company)

· Aviva Group Holdings Limited (wholly owned subsidiary of Aviva plc)

· Aviva Life Holdings UK Limited (wholly owned subsidiary of Aviva Group Holdings Limited)

· Friends Life FPG Limited (wholly owned subsidiary of Aviva Life Holdings UK Limited)

· Friends Life FPL Limited (wholly owned subsidiary of Friends Life FPG Limited)

· Friends Life Limited (wholly owned subsidiary of Friends Life FPL Limited)

· Friends Life and Pensions Limited (wholly owned subsidiary of Friends Life Limited)

· Friends Provident International Limited (wholly owned subsidiary of Friends Life and Pensions Limited)

Vectura Group plc published this content on 16 June 2016 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 June 2016 14:54:02 UTC.

Original documenthttp://otp.investis.com/clients/uk/vectura/rns/regulatory-story.aspx?cid=301&newsid=741740

Public permalinkhttp://www.publicnow.com/view/65A7598A83661A7DE098AFBE2CCB8F3C3DE5C91D

Latest news about Vectura Group

Mundipharma and Vectura Announce Plans to Reformulate Fluticasone Propionate/Formoterol Fumarate	Apr. 16	CI
EnBiotix, Inc. announced that it has received $11 million in funding from Vectura Group plc, Cystic Fibrosis Foundation	21-12-28	CI
Philip Morris CEO does not need M&A to hit smoke free goals	21-12-03	RE
Philip Morris International : Raises Lobbying Concerns Over $1.4 Billion Vectura Deal	21-10-25	MT
PMI Global Services, Inc Completes the Acquisition of Vectura Group plc	21-10-19	CI
Vectura Group plc's Equity Buyback announced on September 10, 2019, has expired.	21-10-18	CI
PMI Global Services, Inc. completed the acquisition of Vectura Group plc from AXA Investment Managers S.A., Legal & General Investment Management Limited, The Vanguard Group, Inc. and others.	21-10-18	CI
Vectura Group plc(LSE:VEC) dropped from S&P Global BMI Index	21-10-08	CI
Philip Morris International : Extends Offer Period For Vectura Takeover	21-10-01	MT
Morrisons takeover battle will go to UK auction on Oct. 2	21-09-29	RE
Vectura Group plc(LSE:VEC) dropped from FTSE 250 Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE 250 (Ex Investment Companies) Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE 350 (Ex Investment Companies) Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE 350 Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE All-Share Index	21-09-21	CI
Vectura Group plc(LSE:VEC) dropped from FTSE techMARK All-Share Index	21-09-21	CI
Philip Morris International : to Delist Britain's Vectura on Oct. 19	21-09-20	MT
Vectura : Pharmaceutical Conference Bans Vectura After Takeover By Philip Morris	21-09-20	MT
Augean : Buyout battle for waste management firm Augean headed to auction - regulator	21-09-16	RE
Today on Wall Street: US economy shows resilience, while China falters	21-09-16
Philip Morris seals deal for UK's Vectura despite health group concerns	21-09-16	RE
FTSE Rises, Ashtead Gains After 1Q Profit Boost, Guidance Increase	21-09-16	DJ
Philip Morris Confirms Majority of Vectura Shareholders Agree to Takeover	21-09-16	CI
Philip Morris International : Secures Vectura Takeover with 75% support	21-09-16	MT
BOE Expected to Leave Policy Unchanged Next Week	21-09-16	DJ

Chart Vectura Group

Duration

Period

More charts

Company Profile

Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.

Sector

More about the company